



2018/10-12

AlzChem Group AG

Ulli Seibel, CEO
Andreas Niedermaier, CFO

March 29, 2019



Cautionary note regarding forward-looking statements

By reviewing this information, you acknowledge that the information may be updated, changed or corrected in the discretion of AlzChem Group AG (hereinafter “the Company”) at any time and should not be relied on for any investment decision or any other purpose. No representation or warranty (express or implied) is made as to the information provided to you, and the Company does not accept any liability in respect of the information.

This presentation has been prepared by the Company and it is furnished to you solely for your information and may not be reproduced or redistributed, in whole or in part, to any other person without the consent of the Company. This presentation contains summary information only and does not purport to be comprehensive and is not intended to be (and should not be used as) the sole basis of any analysis or other evaluation.

This presentation contains certain forward-looking statements relating to the business, financial performance and results of the Company and/or the industry in which the Company operates. Forward-looking statements concern future circumstances and results and other statements that are not historical facts, sometimes identified by the words “believes,” “expects,” “predicts,” “intends,” “projects,” “plans,” “estimates,” “aims,” “foresees,” “anticipates,” “targets,” and similar expressions. The forward-looking statements contained in this presentation, including assumptions, opinions and views of the Company or cited from third party sources, are solely opinions and forecasts which are uncertain and subject to risks. Actual events may differ significantly from any anticipated development due to a number of factors, including without limitation, changes in general economic conditions, in particular economic conditions in Germany, changes affecting interest rate levels, changes in electricity or energy prices, changes in competition levels, changes in laws and regulations, environmental damages and the potential impact of legal proceedings and actions. The Company does not guarantee that the assumptions underlying the forward-looking statements in this presentation are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or any obligation to update the statements in this presentation to reflect subsequent events. The forward-looking statements in this presentation are made only as of the date hereof. The Company does not undertake any obligation to review, update or confirm the content of the presentation.

Unless stipulated otherwise, all values are rounded up or down to nearest Mio.€ euro in accordance with the commercial rounding practices. Please note that differences can result from the use of rounded amounts and percentages.

AGENDA

Analyst presentation 2018/10-12



EXECUTIVE SUMMARY

BUSINESS AND FINANCIAL DETAILS

BACK-UP

HIGHLIGHTS

Summary of operative business full year 2018



FACTS & NUMBERS FOR CALENDAR YEAR 2018

- Record year in sales and EBITDA
- Successful focus on Specialty Chemicals
- Well prepared for start of own distribution of Creamino
- Major CAPEX projects on time and on budget
- Solid sales growth: 375.2 m€ (+ 6.0% vs. prev. year)
- Strong EBITDA : 49.4 m€ (+ 8% vs. prev. year)

OWN DISTRIBUTION OF CREAMINO

Well prepared for the start



CREAMINO
ENERGY FOR HEALTHY GROWTH

A product of:
AlzChem
INNOVATION SINCE 1908

Now direct
from the manufacturer.
The source of creatine for animal nutrition.

Contact:
creamino@alzchem.com
call: +49 8621 86-2904
www.alzchem.com/creamino

EFFECTS ON VOLUME


- Q1 2019: one-time effect expected that previous distribution partners empty their warehouses
- Delay of winning new customers in 2nd half year 2018 will end in January 2019
- Return to normal growth rates in Q2 2019 expected

CREAMINO
ENERGY FOR HEALTHY GROWTH

EFFECTS ON MARGIN

- Evonik's wholesale margin to shift to AlzChem
- New production facility gives favorable economies of scale

CREAMINO IN USE



STRONG POSITION FOR FURTHER GROWTH

IP and patent ownership

- Owner of Creamino patents
- Production know-how
- Competence in energy metabolism
- Chemical and nutritional R&D

Quality & Regulatory compliance

- Made in Germany



Integrated production


- Backwards integrated production
- Total quality control
- Two dedicated plants
- Availability of critical raw materials

Brand & Trademark




PROGRESS OF CONSTRUCTION PROJECTS

Projects on budget and on time for start in summer 2019



New production facility
will triple the actual
production capacity



Production of highly
corrosive
chlorinated nitriles
with attractive
margin

Investment secured
with long term
customer contracts

FINANCIAL OVERVIEW 2018



Result within guidance 2018

ALZCHEM GROUP	2017 Q4	2018 10-12	yoy %	2017 II 7-12	2018 II 7-12	yoy %	2017 1-12	2018 ² 1-12	yoy %	Guidance 2018
SALES (in M€)	81.2	88.0	8.4%	171.1	180.0	5.2%	353.9	375.2	6.0%	364.5 - 378.7
EBITDA (in M€) ¹	7.4	8.1	8.6%	17.7	18.4	3.8%	45.7	49.4	8.0%	49.0 - 54.0
EBITDA margin (in %)	9.1%	9.2%	0.1 pp	10.4%	10.2%	-0.2 pp	12.9%	13.2%	0.3 pp	12.9% - 14.8%
Earnings per Share (in € ct.)				5.8 ct	6.5 ct	12.4%	20.0 ct	22.2 ct	10.9%	

1) 2017 incl. IPO costs +2.0 m€; thereof Q4 1.1 m€

2) Unaudited; calculated by adding the two short fiscal years

COMMENTS

- Significant sales growth, driven by Specialty Chemicals
- Strong growth in EBITDA
- Non-operating costs of 1.5m EUR due to energy legislation ruling of EC (non-adjusted) – nevertheless, EBITDA margin was improved

AGENDA

Analyst presentation 2018/10-12



EXECUTIVE SUMMARY

BUSINESS AND FINANCIAL DETAILS

BACK-UP

BASICS & INTERMEDIATES SEGMENT

Our integrated system



DESCRIPTION

The "Basics & Intermediates" segment comprises the production of **basic and intermediate products** that are marketed as independent products - for example in agriculture, steel production and the automotive sector - and as raw materials for the manufacture of specialty chemicals.

SELECTED PRODUCTS




NITRALZ®




BASICS & INTERMEDIATES SEGMENT

Segment analysis – financial overview (m€)


SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

10-12 2017 vs. 10-12 2018	+ 8.0% Volume	+ 0.4% Price	+ 0.4% FX
1-12 2017 vs. 1-12 2018	- 0.1% Volume	- 0.2% Price	- 0.3% FX

COMMENTS

- 10-12 sales 9% above previous year level
- EBITDA negatively impacted by raw material prices (mainly black materials)
- Strong DCD & NITRALZ® sales
- Slightly weaker metallurgic business
- Higher spot prices for electricity

SPECIALTY CHEMICALS SEGMENT

Our growth focus



DESCRIPTION

The "Specialty Chemicals" segment produces and sells **high-quality growth products** in the area of specialty chemicals.

SELECTED PRODUCTS

 **Creapure**[®]

CREAMINO

DYHARD[®]

Bioselect[®]


 **Dormex**[®]




SPECIALTY CHEMICALS SEGMENT

Segment analysis – financial overview (m€)

SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

10-12 2017 vs. 10-12 2018	+ 7.0% Volume	+ 3.0% Price	+ 0.8% FX
1-12 2017 vs. 1-12 2018	+ 12.8% Volume	+1.2% Price	- 1.0% FX

COMMENTS

- 10-12 sales sharply above previous year level
- Creamino business continues to grow very strongly
- Most products exceed last year Q4 sales
- Positive effect due to USD exchange rate in 10-12 compared to previous year Q4
- Specialty Chemicals also saw increases in raw material costs (mainly Glycin)

OTHER & HOLDING SEGMENT

Further activities



DESCRIPTION

The "Other & Holding" segment comprises all other activities that cannot be allocated to the other segments. The segment offers **infrastructure and energy** supply services at our locations for the chemicals segments and for external customers.




OTHER & HOLDING SEGMENT


Segment analysis – financial overview (m€)




SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

10-12 2017 vs. 10-12 2018	- 11.2% Volume	+ 1.5% Price	± 0% FX
1-12 2017 vs. 1-12 2018	- 7.1% Volume	+ 1.5% Price	± 0% FX

COMMENTS


- Sales volume follows customers site business
- Higher costs for revaluation of the landfill provision due to extension of landfill lifetime
- Less project costs (IPO)
- Lower technical expenses, focus of own capacity on CAPEX projects

BALANCE SHEET


AlzChem Group (m€)



ASSETS




LIABILITIES



CASH FLOW

Growth CAPEX is the basis for further growth




COMMENTS

- Higher operating cash flow due to good business performance
- Higher investing cash flow primarily due to main projects like Creamino and NITRALZ®


OUTLOOK 2019

Sales and earnings growth to continue (m€)

SALES



Adj. EBITDA



COMMENTS

- Sales growth will be organically driven both by Specialty Chemicals and Basics & Intermediates business
- Further reduced dependence on Basics & Intermediates
- Raw material markets expected to settle at a high level (previous year: increase in raw material costs)
- Start-up costs for the new facilities (Creamino and NITRALZ®)

Assumptions

- No significant changes in market interest rates
- Overall economic growth of 2.2% assumed – no economic turmoil (USA, China)
- Stability in product registration and energy legislation
- US dollar forecast: 1.15 € / US\$

Factors to watch

- Continued close monitoring of raw material prices
- Construction of major CAPEX projects will require full attention
- Focused development of Creamino own distribution

FINANCIAL CALENDAR

Upcoming dates



2019	MAY 10	Quarterly Statement 1 st Quarter 2019
2019	MAY 14	General Meeting 2019
2019	MAY 15	Frühjahrskonferenz 2019, Frankfurt
2019	AUG 14	Half-Year Financial Report 2019
2019	NOV 14	Quarterly Statement 3 rd Quarter 2019
2019	NOV 25-27	Deutsches Eigenkapitalforum



 **1,543**
EMPLOYEES


m €
~375
SALES

m €
~49
EBITDA

m €
~35
OPERATING
CASHFLOW

 **ALZCHEM
PRODUCTS
ARE SOLD
WORLDWIDE**

INNOVATION SINCE
1908



All financial indicators relating to January to December 2018



THANK YOU
FOR YOUR ATTENTION!

CONTACT

Investor Relations

T +49 8621 86-2888

F +49 8621 86-502888

ir@alzchem.com

WWW.ALZCHEM.COM

AGENDA

Analyst presentation 2018/10-12



EXECUTIVE SUMMARY

BUSINESS AND FINANCIAL DETAILS

BACK-UP

BALANCE SHEET

AlzChem Group



ASSETS	31.12.2017	30.06.2018	31.12.2018
NON-CURRENT ASSETS			
Intangible assets	1.0	1.0	0.9
Tangible assets	115.1	123.2	144.3
Investment properties			
Investments accounted for using the equity method			
Financials assets	0.0	0.0	0.0
Trade receivables			
Other receivables	1.1	1.1	0.9
Deferred tax assets	25.4	24.6	25.0
SUM NON-CURRENT ASSETS	142.7	149.9	171.0
CURRENT ASSETS			
Inventories	71.4	75.6	78.9
Trade receivables	35.0	52.3	34.4
Financial assets		0.0	0.0
Other receivables	16.3	14.5	14.5
Income tax receivables	2.0	2.3	2.0
Cash and cash equivalents	12.8	9.8	12.9
Assets classified as held for sale			
Other assets			
SUM CURRENT ASSETS	137.5	154.6	142.6
SUM ASSETS	280.2	304.5	313.6

EQUITY & LIABILITIES	31.12.2017	30.06.2018	31.12.2018
EQUITY			
SHARE TO THE SHAREHOLDERS	55.7	72.6	67.0
Non-controlling interests	2.2	1.4	1.4
SUM EQUITY	57.9	74.0	68.4
NON-CURRENT LIABILITIES			
Provisions for pensions	107.2	107.2	110.0
Other provisions	17.4	18.3	18.9
Loans	19.2	16.4	32.6
Finance lease liabilities	0.2	0.2	
Other liabilities	0.0	0.7	0.5
Deferred tax liabilities	2.2	2.2	2.1
SUM NON-CURRENT LIABILITIES	146.3	145.0	164.0
CURRENT LIABILITIES			
Other provisions	1.2	3.5	2.6
Loans	22.1	22.3	25.4
Finance liabilities		0.0	0.0
Trade liabilities	28.2	30.6	30.9
Other liabilities	23.4	26.0	20.9
Income tax liabilities	1.1	3.0	1.5
SUM CURRENT LIABILITIES	76.0	85.4	81.2
Sum EQUITY AND LIABILITIES	280.2	304.5	313.6

INCOME STATEMENT

AlzChem Group



ALZCHEM GROUP (IN T€)	Q4										YTD			
	01.01.2017 - 31.03.2017	01.04.2017 - 30.06.2017	01.07.2017 - 30.09.2017	01.10.2017 - 31.12.2017	01.01.2018 - 31.03.2018	01.04.2018 - 30.06.2018	01.07.2018 - 30.09.2018	01.10.2018 - 31.12.2018	Deviation (Q4)		31.12.2017	31.12.2018	Dev. YOY	
Revenue	91.161	91.653	89.909	81.197	94.522	100.719	91.960	88.009	6.812	8%	353.920	375.210	21.289	26%
Changes in inventories of finished goods and work in progress	1.082	455	-2.498	2.729	5.337	-547	-2.527	3.198	469	17%	1.768	5.461	3.693	135%
Other income	2.903	2.331	2.336	4.024	2.589	4.010	2.370	4.464	440	11%	11.594	13.432	1.838	46%
Raw materials and consumables used	-33.644	-35.279	-36.441	-32.506	-40.876	-39.304	-37.677	-37.565	-5.059	16%	-137.870	-155.422	-17.552	54%
Employee benefits expense	-28.229	-27.970	-25.625	-27.425	-29.123	-29.502	-26.917	-28.640	-1.216	4%	-109.248	-114.183	-4.935	18%
Other expense	-19.866	-16.673	-17.358	-20.598	-17.392	-19.474	-16.806	-21.470	-872	4%	-74.496	-75.142	-646	3%
EBITDA	13.408	14.517	10.322	7.422	15.057	15.902	10.403	7.995	573	8%	45.669	49.357	3.688	50%
Depreciation expense	-3.380	-3.444	-3.483	-3.683	-3.720	-3.777	-3.748	-3.941	-258	7%	-13.990	-15.186	-1.196	32%
EBIT	10.028	11.072	6.839	3.739	11.337	12.124	6.655	4.055	315	8%	31.679	34.170	2.492	67%
Investment income		17	6	15	9	29	30	11	-4	-25%	37	78	41	280%
Other interest and similar income	13	285	113	213	84	194	162	25	-188	-88%	624	465	-160	-75%
Other interest and similar expense	-643	-713	-962	-685	-697	-725	-771	-622	63	-9%	-3.004	-2.816	188	-27%
Financial result	-630	-410	-844	-458	-604	-503	-580	-587	-129	28%	-2.342	-2.273	69	-15%
Result from associates														
Result from ordinary business	9.397	10.662	5.996	3.281	10.733	11.621	6.075	3.468	187	6%	29.336	31.897	2.560	78%
Taxes on income and profit	-2.419	-2.994	-1.635	-1.717	-2.846	-3.445	-1.672	-1.170	547	-32%	-8.765	-9.134	-369	21%
<i>thereof income tax</i>	-2.043	-2.765	-1.400	417	-2.815	-2.992	-1.520	-1.278	-1.695	-407%	-5.791	-8.606	-2.815	-675%
<i>thereof change from deferred taxes</i>	-376	-229	-236	-2.134	-31	-453	-152	108	2.242	-105%	-2.973	-528	2.446	-115%
Annual result	6.979	7.668	4.360	1.564	7.886	8.176	4.403	2.298	733	47%	20.572	22.763	2.191	140%
<i>thereof minority interests</i>	90	54	23	11	-16	73	39	43	32	290%	179	138	-41	-369%
<i>thereof shares held by shareholders</i>	6.888	7.614	4.337	1.553	7.902	8.104	4.364	2.255	702	45%	20.393	22.625	2.232	144%
Result per share in EUR (calculated with 101.763 shares)	0,07 €	0,08 €	0,04 €	0,02 €	0,08 €	0,08 €	0,04 €	0,02 €	0,01 €	47%	0,20 €	0,22 €	0,02 €	140%

CASH FLOW

AlzChem Group



CASHFLOW [m€]	1-6 / 2017	1-6 / 2018	yoy %	7-12 / 2017	7-12 / 2018	yoy %	1-12 / 2017	1-12 / 2018	yoy %
OPERATING CASHFLOW	14.0	15.4	10.0%	16.6	19.2	15.7%	30.7	34.7	13.0%
INVESTING CASHFLOW	-7.4	-15.7	112.2%	-17.3	-24.2	39.9%	-24.8	-39.9	60.9%
FREE CASHFLOW	6.6	-0.3	-104.5%	-0.7	-4.9	600.0%	5.9	-5.2	-188.1%
RAISING / REPAYMENT FROM LOANS	-2.8	-2.6	7.1%	-2.0	16.7	935.0%	-4.8	14.1	393.8%
PAYMENT / DEPOSIT FROM SHORT-TERM CREDIT LINES	14.0	-0.1	-100.7%	1.7	2.6	-52.9%	15.7	2.5	84.1%
DIVIDENDS PAID	-17.8		-100.0%		-11.2		-17.8	-11.2	-37.1%
PAYMENT FROM CAPITAL INCREASE				2.6		-100.0%	2.6		-100.0%
COST OF CAPITAL INCREASE W/O TAX EFFECT				-0.7		-100.0%	-0.7		-100.0%
PAYMENT PROFIT CLAIM OF NON-CONTROLLING INTERESTS					-0.1			-0.1	
NET CASH FROM FINANCING ACTIVITIES	-6.5	-2.7	-58.5%	1.5	8.0	433.3%	-5.1	5.3	-203.9%
NET INCREASE / DECREASE CASH AND CASH EQUIVALENTS	0.0	-3.0		0.8	3.0	275.0%	0.8	0.0	-100.0%

SEGMENT OVERVIEW BY QUARTER




AlzChem Group


SALES [m€]	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	7-9 2018	10-12 2018	1-12 2017 YTD	1-12 2018 YTD	yoy %
SPECIALTY CHEMICALS	48.7	47.8	45.1	44.1	53.9	56.8	49.8	48.9	185.7	209.4	12.8%
BASICS & INTERMEDIATES	35.7	37.0	37.8	30.3	34.2	36.9	35.9	33.0	140.9	140.0	-0.6%
OTHER & HOLDING	6.8	6.8	7.0	6.8	6.5	7.0	6.3	6.1	27.4	25.8	-5.7%
GROUP CONSOLIDATION	0.0	0.0	-0.1			0.0	0.0		-0.1	0.0	
ALZCHEM GROUP	91.2	91.7	89.9	81.2	94.5	100.7	92.0	88.0	272.7	375.2	37.6%

EBITDA [m€]	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	7-9 2018	10-12 2018	1-12 2017 YTD	1-12 2018 YTD	yoy %
SPECIALTY CHEMICALS	11.0	12.0	9.1	10.7	12.6	16.1	9.5	12.4	32.1	50.7	58.2%
BASICS & INTERMEDIATES	2.2	2.6	1.7	-0.9	1.1	0.2	0.1	-2.2	6.5	-0.9	-113.7%
OTHER & HOLDING	-0.6	-0.3	0.1	-1.9	0.8	-0.3	0.5	-0.9	-0.7	0.2	126.2%
GROUP CONSOLIDATION	0.8	0.2	-0.7	-0.4	0.6	-0.1	0.2	-1.3	0.4	-0.6	
ALZCHEM GROUP	13.4	14.5	10.3	7.4	15.1	15.9	10.3	8.1	38.2	49.4	29.1%


SALES SPECIALTY CHEMICALS




SALES BASICS & INTERMEDIATES



SALES OTHER & HOLDING



PENSION ACCOUNTING (IFRS)



COMMENTS

- Slight adjustment of market interest rate from 1.75% → 1.90% as well as new morality tables from Heubeck included
- Continued low cash payments

Executive Team

Experienced management to deliver on the next phase



ULLI SEIBEL



ANDREAS NIEDERMAIER



KLAUS ENGLMAIER

CURRENT POSITION	CEO (since 2009)	CFO (since 2010)	COO (since 2016)
WITH ALZCHEM SINCE ¹	2009	1999	1988
DEGREE	Industrial Engineering	Industrial Engineering	Mechanical Engineering
AREAS OF RESPONSIBILITY	<ul style="list-style-type: none"> • Company Strategy • Investor Relations • Sales • Marketing • R&D 	<ul style="list-style-type: none"> • Finance & Controlling • IT • Supply Chain Management • Legal (Patents & Trademarks) • HR & Social 	<ul style="list-style-type: none"> • Production • Engineering • Environment, Safety, Health, Quality • Technology

ALZCHEM GROUP LOCATIONS

Production sites and sales companies



- SALES COMPANY
- PRODUCTION SITE




TROSTBERG (GER)



SCHALCHEN (GER)



HART a. d. ALZ (GER)



WALDKRAIBURG (GER)

Fully Integrated Business Model (“Verbund”- System)

Ability to adapt production to satisfy changing end market needs



THE “VERBUND-SYSTEM”

- Fully integrated production network
- The output of a production step serves as the basic input for the next production step.
- Cost benefits
- Highly specialized production chain as a unique selling point
- Full control over the quality and specification of all products

MEGATRENDS AS GROWTH DRIVERS

Growth of the population



Healthy aging



Energy efficiency





OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries

	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
SPECIALTY CHEMICALS	CREAMINO	A feed additive for broilers and pigs	Feed additive
	Creapure®	Premium brand for creatine monohydrate as a food supplement in sports nutrition	Food supplements
	Alipure®	Alpha lipoic acid for dog food and food supplements	Food supplements
	Dormex®	Plant growth regulator used in fruit production	Agriculture
	BREATHRU'S 301	Additive for plant protection formulations	Agriculture
	Sitofex®	Plant growth regulator used in fruit production	Agriculture
	Alzogur®	Biocide for the prevention of diseases in animal production	Agriculture
	Silzot[®] SQ	Silicon nitride powder for the solar industry	Photovoltaics
	Silzot[®] HQ	Silicon nitride powder for ceramic applications	Ceramics
	Bioselect®	Highly purified form of guanidine hydrochloride salts	Pharmaceuticals / API
	Cyanamide	An organic compound widely used in agriculture and pharmaceuticals	Agriculture and pharmaceuticals
	DYHARD®	Hardeners and accelerators in powder, paste and liquid form	Hardener & Accelerator Systems for Composite Materials
	Thiourea	Various applications incl. flotation agents and pharmaceutical raw materials	Mining and pharmaceuticals
	Nitroguanidine	Intermediates for agrochemical products	Various

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries

	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
BASICS & INTERMEDIATES	 CaD [®]	Calcium carbide-based mixtures for hot metal desulphurization	Steel industry
	Guanidine Salts	Fuel for airbags, key production of the intermediate product	Automotive
	Dicyandiamide	Versatile intermediate in various markets including the pharmaceutical industry	Pharmaceutical Agriculture
	Nitrile	Business fields in color, agro and pharmaceutical applications	Pigments Pharmaceutical
	 Perlka [®]	Special calcium cyanamide multi-effect fertilizer	Agriculture
OTHER & HOLDING	Other activities not included in the "Specialty Chemicals" or "Basics & Intermediates" segments		
	Operation of the Trostberg Chemical Park (companies located at the site: AlzChem, BASF, Evonik, Aramark, VIActiv, Degussa Bank)		
	Site services		

ALZCHEM SHARE

Share Details 29.03.2019



ISIN / WKN	DE000A0AHT46 / A0AHT4
TICKER SYMBOL	SFP1
TYPE AND NUMBER OF SHARES	101,763,355 bearer shares with no par value (par value shares)
STOCK EXCHANGES	Regulated Market (Prime Standard)
DESIGNATED SPONSOR	Baader Bank AG

SHAREHOLDER STRUCTURE	%
LIVIA Corporate Development SE	37.7
HDI Vier CE GmbH	20.4
Four two na GmbH	15.8
Free Float*	26.1
Including M&G Investment Management Limited	7.6
Including Ulli Seibel	4.9

